Maximizing Reproducibility And Sensitivity In qPCR for Detecting Transcripts Over A Broad Dynamic Range In Response To Anti-PD-1 Therapy

Quantitative PCR (qPCR) remains a cornerstone technique for evaluating gene expression, especially in the context of immunotherapy response monitoring. As immune checkpoint inhibitors — such as anti-PD-1 therapies — continue to transform cancer treatment, the need for precise and reliable quantification of immune-related gene expression has become increasingly important for assessing therapeutic efficacy and guiding personalized care.

This study focuses on optimizing qPCR protocols to enhance both reproducibility and sensitivity in detecting immune-related transcripts in patients receiving anti-PD-1 therapy. Through refined assay conditions, rigorous quality control, and robust normalization strategies, we aim to improve the accuracy and consistency of biomarker measurement. These enhancements support more confident identification of patients most likely to benefit from checkpoint inhibitor therapies, ultimately contributing to more effective, individualized treatment approaches in cancer immunotherapy.